Spermosens AB (SPERM.ST)
SEK 0.01
(2.27%)
SEK 0.01
(2.27%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 13.41 Million SEK | 249.75% |
| 2022 | 3.83 Million SEK | 87.9% |
| 2021 | 2.04 Million SEK | -68.69% |
| 2020 | 6.51 Million SEK | 1405.31% |
| 2019 | 433 Thousand SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 3.17 Million SEK | -78.87% |
| 2024 Q3 | 3.02 Million SEK | -4.57% |
| 2024 Q1 | 15 Million SEK | 11.83% |
| 2023 Q4 | 13.41 Million SEK | 7.36% |
| 2023 FY | 13.41 Million SEK | 249.75% |
| 2023 Q3 | 12.49 Million SEK | 257.56% |
| 2023 Q2 | 3.49 Million SEK | 10.36% |
| 2023 Q1 | 3.16 Million SEK | -17.44% |
| 2022 Q1 | 3.74 Million SEK | 83.49% |
| 2022 FY | 3.83 Million SEK | 87.9% |
| 2022 Q4 | 3.83 Million SEK | 30.75% |
| 2022 Q3 | 2.93 Million SEK | -17.08% |
| 2022 Q2 | 3.53 Million SEK | -5.55% |
| 2021 Q4 | 2.04 Million SEK | -11.57% |
| 2021 Q1 | 6.62 Million SEK | 1.58% |
| 2021 Q3 | 2.3 Million SEK | 12.75% |
| 2021 Q2 | 2.04 Million SEK | -69.08% |
| 2021 FY | 2.04 Million SEK | -68.69% |
| 2020 Q4 | 6.51 Million SEK | 0.0% |
| 2020 FY | 6.51 Million SEK | 1405.31% |
| 2019 FY | 433 Thousand SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AroCell AB (publ) | 11.24 Million SEK | -19.269% |
| Devyser Diagnostics AB (publ) | 125 Million SEK | 89.27% |
| Immunovia AB (publ) | 31.69 Million SEK | 57.674% |
| Prostatype Genomics AB (publ) | 24.54 Million SEK | 45.36% |
| SenzaGen AB | 29.56 Million SEK | 54.637% |